Home » DSM Receives Profiles in Sustainability Award for Pharma Manufacturing Technology
DSM Receives Profiles in Sustainability Award for Pharma Manufacturing Technology
PharmaManufacturing.com
02/23/2010
DSM Pharmaceutical Products, based in Parsippany, NJ, recently announced that it has received a Profiles in Sustainability award from United Business Media and ICIS Chemical Business. United Business Media Limited is a leading global business media company and parent of InformexUSA, where the award was announced today in San Francisco. Organized by UBM International Media, Informex, taking place February 16-19, 2010, at San Francisco's Moscone Center South, is the leading meeting place for buyers and sellers of high-value chemistry for a broad range of applications.
DSM was considered based on its process intensification activities, such as micro reactor technology, and their "green chemistry toolbox" for the sustainable, cost-effective production of active pharmaceutical ingredients. "This represents our commitment to understanding our customers' needs and the need for viable manufacturing solutions in the future." stated Bob Hartmayer, President and CEO of DSM Pharmaceutical Products. As part of DSM's global commitment to sustainability, for six years DSM has ranked at the top of the Dow Jones Sustainability Index due to its continuous drive to embed sustainability metrics into process design and manufacturing, and to provide transparency about this in the annual Triple P (People, Planet, Profit) report.
"The Profiles in Sustainability award was born from a need to recognize that sustainable chemistry was not just a passing fad or a niche branch for the chemical industry. Informex is leading the way in bringing green chemistry to the forefront in traditional chemical forums. We were overwhelmed at the outpouring of interest in the award, and the quality of the papers. The real factor that made our winners stand-out was their current viability in the market." stated Jennifer Jessup, brand director of Informex.
A panel of industry experts coordinated by ICIS selected five submitting companies to be recognized. "DSM is proud of its broad technological toolbox in chemistry, biology, and process technology and material sciences, which strongly contribute to our leadership position in sustainable manufacturing. Also, optimizing first generation processes by driving down the cost curve is crucial for the commercial success of pharmaceutical compounds," commented Luca Mantovani, President and Business Unit Director of DSM Pharma Chemicals. DSM's green chemistry tool box is increasingly used to bring down these manufacturing costs and at the same time "green-up" the process. The DSM tool box involves chemo- and biocatalysis, process intensification, and the proactive management of learning curves to increase yield and reduce waste.
DSM also exhibited as part of Informex Pharma and at the Green Chemistry Pavilion as well as speaking at the Green Chemistry Breakfast Briefing developed in partnership with the American Chemical Society's Green Chemistry Institute, of which DSM is an associate member of the Pharmaceutical Roundtable.
More News:
-
06/18/2013
Aragon Purchased For $650M+From USA Today
Johnson & Johnson has agreed to buy Aragon Pharmaceuticals for at least $650 million in cash.
-
06/18/2013
ASME BPE Certifies MaxPure Stainless-Steel Fittings
TEK Stainless Piping Products announces certification of MaxPure, EGMO’S stainless-steel fitting product line for bioprocessing industry
-
06/18/2013
Supreme Court Rules Against 'pay-to-delay'From Economic Times
Big pharma companies lose in Supreme Court's 'pay-to-delay' decision.
-
06/18/2013
BioScrip Acquires CarePoint for $223 MillionFrom Bloomberg Businessweek
BioScrip Inc. plans to expand its drug infusion business with a new acquisition of CarePoint for $223 million.
-
06/17/2013
Endress+Hauser Offers Online Thermowell Sizing Calculator
Free, online thermowell calculation tool compliant with new ASME PTC 19.3 TW-2010 standards simplifies engineer work
-
06/14/2013
Supreme Court DNA Ruling Could Hurt Biotech IndustryFrom The Denver Post Politics
Critics said the ruling would discourage other companies and financial backers from investing in more genetic sequencing research
-
06/14/2013
Supreme Court Says No to Patenting Human GenesFrom The Scientist
The Court unanimously ruled that isolated sequences of human DNA are not eligible for patent protection, but artificial sequences can be patented
-
06/13/2013
All-new Pharma EXPO Debuts in November 2014
Co-located with PACK-EXPO International, ISPE Pharma EXPO will be held in Chicago
-
06/13/2013
Canadian Health Authority Accepts Use of Roche's Rapid Mycoplasma Detection TestFrom Roche
Roche’s Rapid Mycoplasma Detection Test MycoTOOL Receives Acceptance from Canadian Authorities for Release Testing of Biopharmaceutical Roche Product
-
06/13/2013
Over 200 Cardiovascular Disease Drugs in DevelopmentFrom Drug Store News
According a recent report, 215 drugs are now under development for heart disease and stroke.
- All news »
Get Connected Now!
- Featured White Papers

Print page